Pfizer Inc’s PFE.N experimental COVID-19 vaccine projects promising result in phase 3 trial, Nov 10, 2020. [Photo: Quartz]

Pfizer Inc’s PFE.N experimental COVID-19 vaccine projects promising result in phase 3 trial, said the pharmaceutical company Monday, sharing joy over a 90 percent victory in the war against growing respiratory illness known as coronavirus.

The novel coronavirus that has killed over a million people and battered world’s economy, triggered global efforts to produce vaccine that can potentially safe millions at risk of the virus.

Pfizer and German partner BioNTech SE 22UAy.F said they had found no serious safety concerns yet and expected to seek U.S. emergency use authorization this month, as Reuters reported, raising the chance of a regulatory decision as soon as December.

While the move awaits authorization, companies estimates they can roll out up to 50 million doses this year, and then produce up to 1.3 billion doses in the year to come.

“Today is a great day for science and humanity,” said Pfizer Chief Executive Albert Bourla, noting the data milestone comes with “infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen.”

Although there are still many questions as to how effective the vaccine is by ethnicity or age and how long immunity may last, health experts shares common joy for such a breakthrough that show above 90 percent victory in pandemic battle.  

Author


  • Muhammad Arif Sheva holds a B.A degree in Journalism from Int'l Peace Leadership College Rizal, Philippines. Sheva works as an editor and content writer for Khaama Press.